{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:59:04Z","timestamp":1786982344449,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fondo de Investigaciones Sanitarias del Instituto de Salud Carlos III","award":["PI16\/01627"],"award-info":[{"award-number":["PI16\/01627"]}]},{"name":"Fondo de Investigaciones Sanitarias del Instituto de Salud Carlos III","award":["PI17\/01925"],"award-info":[{"award-number":["PI17\/01925"]}]},{"name":"Fondo de Investigaciones Sanitarias del Instituto de Salud Carlos III","award":["PI17\/01232"],"award-info":[{"award-number":["PI17\/01232"]}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CB16\/11\/00261"],"award-info":[{"award-number":["CB16\/11\/00261"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. of Cardiovasc. Trans. Res."],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Transcriptomic signature of\n                    <jats:italic>XPO1<\/jats:italic>\n                    was highly expressed and inversely related to left ventricular function in ischemic cardiomyopathy patients. We hypothesized that treatment with AAV9-shXPO1 attenuates left ventricular dysfunction and remodeling in a myocardial infarction rat model. We induced myocardial infarction by coronary ligation in Sprague-Dawley rats (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200910), which received AAV9-shXPO1 (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20095) or placebo AAV9-scramble (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20095) treatment. Serial echocardiographic assessment was performed throughout the study. After myocardial infarction, AAV9-shXPO1-treated rats showed partial recovery of left ventricular fractional shortening (16.8\u2009\u00b1\u20092.8 vs 24.6\u2009\u00b1\u20094.1%,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.05) and a maintained left ventricular dimension (6.17\u2009\u00b1\u20090.95 vs 4.70\u2009\u00b1\u20090.93\u00a0mm,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.05), which was not observed in non-treated rats. Furthermore, lower levels of EXP-1 (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.05) and lower collagen fibers and fibrosis in cardiac tissue were observed. However, no differences were found in the IL-6 or TNFR1 plasma levels of the myocardium of AAV9-shXPO1 rats. AAV9-shXPO1 administration attenuates cardiac dysfunction and remodeling in rats after myocardial infarction, producing the gene silencing of\n                    <jats:italic>XPO1<\/jats:italic>\n                    .\n                  <\/jats:p>","DOI":"10.1007\/s12265-019-09932-y","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T11:03:51Z","timestamp":1574679831000},"page":"593-600","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["XPO1 Gene Therapy Attenuates Cardiac Dysfunction in Rats with Chronic Induced Myocardial Infarction"],"prefix":"10.1007","volume":"13","author":[{"given":"Mar\u00eda","family":"Garc\u00eda-Manzanares","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefan\u00eda","family":"Taraz\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Gil-Cayuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Mart\u00ednez-Dolz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Ram\u00f3n","family":"Gonz\u00e1lez-Juanatey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisca","family":"Lago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4415-7160","authenticated-orcid":false,"given":"Manuel","family":"Portol\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Rosell\u00f3-Llet\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,25]]},"reference":[{"issue":"9963","key":"9932_CR1","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","volume":"385","author":"GBD Mortality","year":"2015","unstructured":"Mortality, G. B. D. (2015). Causes of death C: global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 385(9963), 117\u2013171.","journal-title":"Lancet"},{"issue":"9474","key":"9932_CR2","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1016\/S0140-6736(05)66621-4","volume":"365","author":"JJ McMurray","year":"2005","unstructured":"McMurray, J. J., & Pfeffer, M. A. (2005). Heart failure. Lancet, 365(9474), 1877\u20131889.","journal-title":"Lancet"},{"issue":"18","key":"9932_CR3","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1136\/heartjnl-2012-301623","volume":"98","author":"AM van der Laan","year":"2012","unstructured":"van der Laan, A. M., Nahrendorf, M., & Piek, J. J. (2012). Healing and adverse remodelling after acute myocardial infarction: role of the cellular immune response. Heart, 98(18), 1384\u20131390.","journal-title":"Heart"},{"issue":"4","key":"9932_CR4","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.yjmcc.2009.10.033","volume":"48","author":"D Phillips","year":"2010","unstructured":"Phillips, D., Ten Hove, M., Schneider, J. E., Wu, C. O., Sebag-Montefiore, L., Aponte, A. M., Lygate, C. A., Wallis, J., Clarke, K., Watkins, H., et al. (2010). Mice over-expressing the myocardial creatine transporter develop progressive heart failure and show decreased glycolytic capacity. Journal of Molecular and Cellular Cardiology, 48(4), 582\u2013590.","journal-title":"Journal of Molecular and Cellular Cardiology"},{"issue":"1","key":"9932_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1093\/cvr\/cvq240","volume":"88","author":"MG Rosca","year":"2010","unstructured":"Rosca, M. G., & Hoppel, C. L. (2010). Mitochondria in heart failure. Cardiovascular Research, 88(1), 40\u201350.","journal-title":"Cardiovascular Research"},{"issue":"3","key":"9932_CR6","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/ehf2.12085","volume":"3","author":"A Ortega","year":"2016","unstructured":"Ortega, A., Rosello-Lleti, E., Tarazon, E., Gil-Cayuela, C., Lago, F., Gonzalez-Juanatey, J. R., Martinez-Dolz, L., Portoles, M., & Rivera, M. (2016). TRPM7 is down-regulated in both left atria and left ventricle of ischaemic cardiomyopathy patients and highly related to changes in ventricular function. ESC Heart Fail, 3(3), 220\u2013224.","journal-title":"ESC Heart Fail"},{"issue":"2","key":"9932_CR7","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/jcmm.12477","volume":"19","author":"E Rosello-Lleti","year":"2015","unstructured":"Rosello-Lleti, E., Tarazon, E., Barderas, M. G., Ortega, A., Molina-Navarro, M. M., Martinez, A., Lago, F., Martinez-Dolz, L., Gonzalez-Juanatey, J. R., Salvador, A., et al. (2015). ATP synthase subunit alpha and LV mass in ischaemic human hearts. Journal of Cellular and Molecular Medicine, 19(2), 442\u2013451.","journal-title":"Journal of Cellular and Molecular Medicine"},{"issue":"3","key":"9932_CR8","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1093\/cvr\/cvp336","volume":"85","author":"R Cortes","year":"2010","unstructured":"Cortes, R., Rosello-Lleti, E., Rivera, M., Martinez-Dolz, L., Salvador, A., Azorin, I., & Portoles, M. (2010). Influence of heart failure on nucleocytoplasmic transport in human cardiomyocytes. Cardiovascular Research, 85(3), 464\u2013472.","journal-title":"Cardiovascular Research"},{"issue":"11","key":"9932_CR9","doi-asserted-by":"publisher","first-page":"e48957","DOI":"10.1371\/journal.pone.0048957","volume":"7","author":"E Tarazon","year":"2012","unstructured":"Tarazon, E., Rivera, M., Rosello-Lleti, E., Molina-Navarro, M. M., Sanchez-Lazaro, I. J., Espana, F., Montero, J. A., Lago, F., Gonzalez-Juanatey, J. R., & Portoles, M. (2012). Heart failure induces significant changes in nuclear pore complex of human cardiomyocytes. PLoS One, 7(11), e48957.","journal-title":"PLoS One"},{"issue":"3","key":"9932_CR10","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1016\/j.ijcard.2013.03.192","volume":"168","author":"MM Molina-Navarro","year":"2013","unstructured":"Molina-Navarro, M. M., Rosello-Lleti, E., Tarazon, E., Ortega, A., Sanchez-Izquierdo, D., Lago, F., Gonzalez-Juanatey, J. R., Garcia-Pavia, P., Salvador, A., Montero, J. A., et al. (2013). Heart failure entails significant changes in human nucleocytoplasmic transport gene expression. International Journal of Cardiology, 168(3), 2837\u20132843.","journal-title":"International Journal of Cardiology"},{"issue":"4","key":"9932_CR11","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1161\/01.RES.0000237661.18885.f6","volume":"99","author":"CA Pacak","year":"2006","unstructured":"Pacak, C. A., Mah, C. S., Thattaliyath, B. D., Conlon, T. J., Lewis, M. A., Cloutier, D. E., Zolotukhin, I., Tarantal, A. F., & Byrne, B. J. (2006). Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circulation Research, 99(4), e3\u2013e9.","journal-title":"Circulation Research"},{"issue":"1","key":"9932_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ymthe.2006.03.014","volume":"14","author":"K Inagaki","year":"2006","unstructured":"Inagaki, K., Fuess, S., Storm, T. A., Gibson, G. A., McTiernan, C. F., Kay, M. A., & Nakai, H. (2006). Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Molecular therapy : the journal of the American Society of Gene Therapy, 14(1), 45\u201353.","journal-title":"Molecular therapy : the journal of the American Society of Gene Therapy"},{"issue":"9","key":"9932_CR13","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1161\/CIRCULATIONAHA.108.783852","volume":"119","author":"L Suckau","year":"2009","unstructured":"Suckau, L., Fechner, H., Chemaly, E., Krohn, S., Hadri, L., Kockskamper, J., Westermann, D., Bisping, E., Ly, H., Wang, X., et al. (2009). Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation, 119(9), 1241\u20131252.","journal-title":"Circulation"},{"issue":"5","key":"9932_CR14","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/0002-8703(81)90226-X","volume":"101","author":"MC Fishbein","year":"1981","unstructured":"Fishbein, M. C., Meerbaum, S., Rit, J., Lando, U., Kanmatsuse, K., Mercier, J. C., Corday, E., & Ganz, W. (1981). Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. American Heart Journal, 101(5), 593\u2013600.","journal-title":"American Heart Journal"},{"issue":"17","key":"9932_CR15","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1016\/j.jacc.2016.02.049","volume":"67","author":"J Aguero","year":"2016","unstructured":"Aguero, J., Ishikawa, K., Hadri, L., Santos-Gallego, C. G., Fish, K. M., Kohlbrenner, E., Hammoudi, N., Kho, C., Lee, A., Ibanez, B., et al. (2016). Intratracheal gene delivery of SERCA2a ameliorates chronic post-capillary pulmonary hypertension: a large animal model. Journal of the American College of Cardiology, 67(17), 2032\u20132046.","journal-title":"Journal of the American College of Cardiology"},{"key":"9932_CR16","first-page":"1271670","volume":"2017","author":"R An","year":"2017","unstructured":"An, R., Xi, C., Xu, J., Liu, Y., Zhang, S., Wang, Y., Hao, Y., & Sun, L. (2017). Intramyocardial injection of recombinant adeno-associated viral vector coexpressing PR39\/adrenomedullin enhances angiogenesis and reduces apoptosis in a rat myocardial infarction model. Oxidative Medicine and Cellular Longevity, 2017, 1271670.","journal-title":"Oxidative Medicine and Cellular Longevity"},{"issue":"12","key":"9932_CR17","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1038\/mt.2014.127","volume":"22","author":"K Ishikawa","year":"2014","unstructured":"Ishikawa, K., Fish, K. M., Tilemann, L., Rapti, K., Aguero, J., Santos-Gallego, C. G., Lee, A., Karakikes, I., Xie, C., Akar, F. G., et al. (2014). Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failure. Molecular therapy : the journal of the American Society of Gene Therapy, 22(12), 2038\u20132045.","journal-title":"Molecular therapy : the journal of the American Society of Gene Therapy"},{"issue":"1","key":"9932_CR18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ab.2005.07.041","volume":"346","author":"AL Winters","year":"2005","unstructured":"Winters, A. L., & Minchin, F. R. (2005). Modification of the Lowry assay to measure proteins and phenols in covalently bound complexes. Analytical Biochemistry, 346(1), 43\u201348.","journal-title":"Analytical Biochemistry"},{"issue":"1","key":"9932_CR19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12967-019-1881-8","volume":"17","author":"AA Sayour","year":"2019","unstructured":"Sayour, A. A., Korkmaz-Icoz, S., Loganathan, S., Ruppert, M., Sayour, V. N., Olah, A., Benke, K., Brune, M., Benko, R., Horvath, E. M., et al. (2019). Acute canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation. Journal of Translational Medicine, 17(1), 127.","journal-title":"Journal of Translational Medicine"},{"issue":"7","key":"9932_CR20","doi-asserted-by":"publisher","first-page":"e0160168","DOI":"10.1371\/journal.pone.0160168","volume":"11","author":"A Ortega","year":"2016","unstructured":"Ortega, A., Gil-Cayuela, C., Tarazon, E., Garcia-Manzanares, M., Montero, J. A., Cinca, J., Portoles, M., Rivera, M., & Rosello-Lleti, E. (2016). New cell adhesion molecules in human ischemic cardiomyopathy. PCDHGA3 implications in decreased stroke volume and ventricular dysfunction. PLoS One, 11(7), e0160168.","journal-title":"PLoS One"},{"issue":"2","key":"9932_CR21","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.ijcard.2012.10.046","volume":"168","author":"JA Finegold","year":"2013","unstructured":"Finegold, J. A., Asaria, P., & Francis, D. P. (2013). Mortality from ischaemic heart disease by country, region, and age: statistics from World Health Organisation and United Nations. International Journal of Cardiology, 168(2), 934\u2013945.","journal-title":"International Journal of Cardiology"},{"issue":"2","key":"9932_CR22","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1073\/pnas.97.2.793","volume":"97","author":"MI Miyamoto","year":"2000","unstructured":"Miyamoto, M. I., del Monte, F., Schmidt, U., DiSalvo, T. S., Kang, Z. B., Matsui, T., Guerrero, J. L., Gwathmey, J. K., Rosenzweig, A., & Hajjar, R. J. (2000). Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proceedings of the National Academy of Sciences of the United States of America, 97(2), 793\u2013798.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"9","key":"9932_CR23","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/eurheartj\/ehs043","volume":"33","author":"R Kumarswamy","year":"2012","unstructured":"Kumarswamy, R., Lyon, A. R., Volkmann, I., Mills, A. M., Bretthauer, J., Pahuja, A., Geers-Knorr, C., Kraft, T., Hajjar, R. J., Macleod, K. T., et al. (2012). SERCA2a gene therapy restores microRNA-1 expression in heart failure via an Akt\/FoxO3A-dependent pathway. European Heart Journal, 33(9), 1067\u20131075.","journal-title":"European Heart Journal"},{"issue":"3","key":"9932_CR24","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.111.022889","volume":"124","author":"M Jessup","year":"2011","unstructured":"Jessup, M., Greenberg, B., Mancini, D., Cappola, T., Pauly, D. F., Jaski, B., Yaroshinsky, A., Zsebo, K. M., Dittrich, H., Hajjar, R. J., et al. (2011). Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation, 124(3), 304\u2013313.","journal-title":"Circulation"},{"issue":"10","key":"9932_CR25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1002\/jgm.1600","volume":"13","author":"NB Wasala","year":"2011","unstructured":"Wasala, N. B., Shin, J. H., & Duan, D. (2011). The evolution of heart gene delivery vectors. The Journal of Gene Medicine, 13(10), 557\u2013565.","journal-title":"The Journal of Gene Medicine"}],"container-title":["Journal of Cardiovascular Translational Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-019-09932-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12265-019-09932-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-019-09932-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T19:49:01Z","timestamp":1606160941000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12265-019-09932-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,25]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["9932"],"URL":"https:\/\/doi.org\/10.1007\/s12265-019-09932-y","relation":{},"ISSN":["1937-5387","1937-5395"],"issn-type":[{"value":"1937-5387","type":"print"},{"value":"1937-5395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,25]]},"assertion":[{"value":"14 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}